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Summary: Recently published blood kinin concentrations are subject a wide scatter, due to sampling time
and technique. In our study we tested the influence of the used antibradykinin antiserum on the measured
kinin concentration in blood. Blood was collected from the anticubital vein by a teflon cannula and inactivated
immediately by hydrochloric acid in the syringe. Subsequent extraction was performed using diethylether, n-
butanol, distilled water and Biorex-70. The blood extract containing the kinins was divided into four samples
and measured by four radioimmunoassays using different antibradykinin antibodies. All four assays were
performed under Standard conditions and at the same time. The resulting kinin values were similar in two
assays: 7.4 ± 2.6 ng/1 and 5.6 ±1.3 ng/1. In the two other assays, however, the measured kinin concentrations
differed markedly from these values: 127.5 ± 46.7 ng/1 and 693.0 ± 85.7 ng/1. These results indicate clearly
that the antibody used in the assay can be a major factor determining the r nge of the recorded kinin
concentration.
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2. antibody Si which was produced by immunisation of rabbits
with bradykinin coupled to edestin by l -ethyl-3-dimethyl-
aminopropyl-carbodiimide (7);
3. antibody Hu which was produced by immunisation of rab-
bits with bradykinin coupled to ovalbumin by toluene-2,4-
diisocyanate (8);
4. antibody Sh which was produced by immunisation of rabbits
with bradykinin coupled to bovine serum albumin by 1-ethyl-
3-dimethylaminopropyl-carbodiimide (9).
In the assay the working dilution of antibody was
16000for07a,
8000 for Si,
50000 for Hu, and
500 000 for Sh.
Tracer
The radiolabelled antigen was prepared according to Green-
wood SL Runter äs previously published (10, 11). [125I-Tyr*]bra-
dykinin was used äs tracer in the assays with antibody 07a, Si
and Hu. [125I-Tyr1]kallidin was used äs tracer in the assay
with antibody Sh for better sensitivity while specifity remained
unchanged. Radioactivity added to the test tube was about
8000 counts/min.
Radioimmun o assay
The radioimmunoassay for determination of bradykinin was
performed äs previously described (11). In each assay, known
control samples were checked for their bradykinin content, in
order to test the assay System. Kinins in the blood sample were
calculated from the Standard curve, only if the corresponding
controls were satisfactory.
Extraction
Peripheral venous blood was obtained from 16 healthy volun-
teers (10 females, 6 males) in sitting position. The technique of
blood sampling and kinin extraction was a modified Version of
that reported by two groups (12,13). A teflon cannula (Viggo®)
was inserted into an antecubital vein and free blood flow was
observed. Without strong drawing 10 ml of blood were collected
into a syringe containing 30 ml of l mol/1 HC1. In this way an
immediate inactivation of all plasma enzymes was achieved,
preventing kinin formation or cleavage. The mixture was added
to 50 ml of diethylether, shaken thoroughly, then centrifuged
for 15 min at 2500 g. After centrifugation the upper layer with
the lipids and the pellet of blood cells were rejected. The kinins
of the remaining fluid were extracted with 50ml (5 10 ml)
of absolute «-butanol. After centrifugation for 15 min at 2500 g
the upper layer was reextracted with 75ml (5 15 ml) of
doubly distilled water. After further centrifugation, the upper
layer was rejected and the remaining fluid was evaporated at
60 °C to dryness. Each sample was redissolved in 60 ml of 0.1
mol/1 acetic acid (pH 4.0). Then this solution was transfered to
a Biorex-70 column ( 1 x 1 cm, Biorad) at a rate of 2 ml per
min. The kinins retained during the ion exchange chromatogra-
phy were eluted from the column by 10 ml of 10 mol/1 acetic
acid (pH 1.0). Thereafter the acetic acid was evaporated at
60 °C to dryness. The extracted sample was redissolved in l ml
of RIA buffer, adjusted to pH 7.4 by 0.1 mol/1 NaOH, and
divided into four identical portions. Each portion was assayed
simultaneously by one of the 4 bradykinin radioimmunoassays
described above. The kinin content of the blood sample was
calculated with regard to the recovery and the sample dilution.
To determine bradykinin recovery in the extraction procedure
500 pg unlabelled bradykinin were added to a secpnd syringe,
which was then used to sample a further 10ml of blood,
immediately after the first 10ml for kinin determination. The
extraction procedure of the recovery sample was the same äs
described for the sample.
Cross-reactivity
Cross-reactivity of antibodies was tested against highly purified
peptides, such äs lys-bradykinin, met-lys-bradykinin, ile-ser-
bradykinin, de-arg9-bradykinin, de-phe8-arg9-bradykinin, de-
arg^bradykinin. Antibody 07a was additionally tested against
the following peptides: arg-pro-pro-gly-phe-ser, pro-pro-gly-
phe-ser-pro, ser-pro, pro-gly, phe-ser, gly-phe, pro-phe, brady-
kinin-potentiator B and C, substance P, neürpt^nsin, eleodoisin,
serotonin, leu-encephalin, angiotensin I, II, and III. Further-
more, cross-reactivity of all four antibodies against bovine and
human low molecular weight (LMW) kininogen and human
serum albumin was studied. The peptides or proteins tested
were purchased from Sigina, Bachern, Serva or they were a gift
from Dr. Kalo. Calculation of cross-reactivity was based on
the molar concentration at the 50% intercept of the dilution
curve:
% cross-reactivity = (BK5o%/X5o%) ' 100
100% of cross-reactivity represents an equimolar reactivity of
the tested compound (X), when eompared with that of bradyki-
nin (BK).
Statistical analysis
Values given represent naeans ± SEM. Statistical significance
of differences between means was calculated according to Kru-
skal & Wallis. Significance was accepted at the 5% level
(p < 0.05).
Results
Using the extraction method described, it was pos-
sible to purify blood kinins for measurement in the
bradykinin radioimmunoassay. The extracted kinin-
like material showed in all four radioimmunoassays
the same immunological reactivity äs highly purified
bradykinin, since the dilution curve of blood extract
paralleled the Standard curve in all four assays, inde->
pendently of the antibradykinin antiserum used (fig.
1). The recovery of cold bradykinin added to the
sample was 52.9 ± 4.0%, the coefficient of intra-
assay Variation of bradykinin measurement in blood
was 9.8%. When the concentration of kinins Was
determined under basal conditions in the blood of 16
volunteers, using the different antibodies in the same
assay, only two antibodies (Sh and Si) measured the
kinin concentration in the same ränge, while the
two other antibodies (07a and Hu) determined quite
different values (Sh: 5.6 ± 1.3 ng/1; Si: 7.4 ± 2.6
ng/1; Hu: 127.5 ± 46.7 ng/1; 07a: 693.0 ± 85.7 ng/1;
fig. 2). The difference in kinin concentration deter-
mined with the aid of antibodies Sh and Si on the
one band, and 07a on the other hand, was highly
significant (p < 0.001). The cross-reactivity of the
antibodies against other kinins like kallidin (lys-bra-
dykinin), T-kinin (ile-ser-bradykinin) and metelys-
bradykinin äs well äs against bradykinin fragments,
low molecular weight kininogen and human serum
albumin was nearly the same in all four tested anti-
bodies (tab. 1). Only antiserum Hu showed high
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Fig. 1. Standard curve (o) and serial dilution curve of extracted blood sample (x) for the bradykinin radioimmunoassay by four
different antibradykinin antisera (07a, Hu, Sh, Si). The curves are presented s logit-log functions.
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Fig. 2. Concentration of kiniiis in blood after extraction deter-
mined by four different antibradykinin antisera (07a,
Hu, Si, Sh) in the same radioimmunoassay System under
identical conditions. The values determined by 07a and
Hu were significantly higher (**: p < 0001) than those
determined by Si and Sh. χ ± SEM; n = 16.
Tab. 1. Comparison of the cross-reactivity of the used four
antibradykinin antisera against other kinins, kinin frag-
ments, low molecular weight (LMW) kininogen and
human serum albumin.
Cross-reactivity in % of bradykinin
using antibody
Sh Si 07a Hu
Peptide/protein:
Bradykinin (BK)
lys-BK
met-lys-BK
de-arg9-BK
de-phe*-arg9-BK
de-arg'-BK
LMW-kininogen,
bovine
LMW-kininogen,
human
Human ser m
albumin
100.0
100.0
100.0
0.02
<0.01
26.8
<0.1
7.5
<0.01
100.0
111.9
77.4
0.02
<0.01
0.25
<0.01
4.2
<0.01
100.0
101.7
85.1
<0.01
<0.01
<0.01
0.7
8.2
<0.01
100.0
97.0
42.0
<0.01
<0.01
82.0
10.5
8.2
<0.01
cross-reactivity with the bradykinin fr gment de-arg1^
bradykinin and a mild cross-reactivity with bovine
and human low molecular weight kininogen. Anti-
body 07a cross-reacted only a little with human low
molecular weight kininogen, but shpwed no cross-
reactivity with any other tested bradykinin fragment
or peptide. Antibodies Sh and Si had little cross-
reactivity with human low molecular weight kinino-
gen, but not with bovine low molecular weight kini-
nogen.
Discussion
Kinins are highly potent peptides involved in many
pathological reactions of the organism, such s al-
lergic hypotension, allergic rhinitis, arthritis, pancrea-
titis, angioneurotic oedema, septic shock, myocardial
infarction or acute respiratory distress syndrome after
polytraumata or severe injuries (14, 15). To elucidate
the pathophysiological role of kinins in these diseases
it is necessary to measure actual kinin levels in blood.
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Since 1964 many methods of kinin determination in
blood have been described (16-22). However, the
reported values for kinins in blood ränge between
4000 and nearly 0 ng/1. The reason for these enor-
mous differences in blood kinin levels are still unclear,
in spite of many methodological investigations. First
of all it was suggested that the determination of kinins
in inactivated plasma samples would present higher
kinin levels than in immediately denatured blood,
because the kallikreins in plasma probably still liber-
ate kinins until their complete inactivation by inhibi-
tors, which are not added until after blood sampling
(4, 5). If the enzymatic activity of the plasma sample
was completely inactivated immediately at the Start
of blood sampling by an inhibitor solution in the
syringe, no differences between blood and plasma
kinin levels were found (13). But promptness in en-
zyme inactivation during blood sampling is not the
only factor influencing the measurement of kinin
concentration in blood, since high kinin levels were
reported even in immediately inactivated blood sam-
ples (6). These findings indicate clearly that there
other additional factors exist influencing the basal
levels of the measured kinins in either blood or
plasma samples.
In our investigation the kinin measurement was per-
formed by four radioimmunoassays simultaneously
under identical conditions. There was no difference
in the tested samples since the blood sample was
divided for the four assays after the last extraction
procedure just before the measurement. In all assays
the dilution curve of blood extract strongly paralleled
the Standard curve, indicating that the kinin-like ma-
terial in blood had an immunoreactivity identical to
that of bradykinin in each radioimmunoassay, Thus,
it was most surprising that the measured kimn levels
were not identical. The kinin concentrations meas-
ured by the antibodies Hu and Sh were in the same
ränge reported in older studies in a major group of
normal man (6, 13). Use of the two other antibodies
of our laboratory resulted in very high and very low
recorded values for the kinin concentration. Thus,
our reported results demonstrate for the first time
that the kinin level in blood depends at least in part
on the antibradykinin antiserum used in the assay.
The reason for this discrepancy in kinin measurement
by the four antibodies is not known. However, it can
be suggested, that cross-reactivity of the antibodies
with fragments of kinins or kininogens probably plays
an important role. This could be true for the higher
kinin levels determined with antibody Hu, since this
antibody has a much higher cross-röactivity agämst
the de-arg^bradykinin fragment than all other anti-
bodies. If this peptide, which could be released by an
aminopeptidase, is present in the blood sample, the
normally used extraction procedures are not able
to separate this peptide from the intact bradykinin
molecule. This might lead to falsely high analytical
values for bradykinin. This aiitibody and antibody
07a also cross-react with bovine low molecular weight
kininogen. However, even if the species (bovine) of
the tested kininogen is ignored, the very small cross-
reactivity with low molecular weight kininogen alone
cannot be responsible for the very high recorded
levels of kinins in blood, since both kininogens, bov-
ine or human, were completely separated from kiriins
by the extraction procedure used in our method.
But the possibility cannot be excluded that sinaller
kininogen fragments, carrying the amino acid se-
quence responsible for an immunological cross-reacr
tivity, are extracted with the kinins, thereby leading
to falsely high analytical values for bradykinin.
Even though there is evidence that the analytical
value for kinin is affected by the cross-reactivity of
the used antibody, we found no cross-reaction of
antibody 07a with all tested (n = 10) bradykinin frag-
ments. Thus, it has to be considered whether an
additional unknown factor in blood extract interferes
with kinin measurement. The question öf the origin
of this factor and why it interferes when only certain
antibodies are used for the kinin measurement, can-
not be answered yet. Further biochemical and immu-
nological investigations are necessary to identify such
a factor.
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